CN113710658A - 用于治疗尤因肉瘤的喹啉类化合物或其药学上可接受的盐 - Google Patents

用于治疗尤因肉瘤的喹啉类化合物或其药学上可接受的盐 Download PDF

Info

Publication number
CN113710658A
CN113710658A CN202080019229.3A CN202080019229A CN113710658A CN 113710658 A CN113710658 A CN 113710658A CN 202080019229 A CN202080019229 A CN 202080019229A CN 113710658 A CN113710658 A CN 113710658A
Authority
CN
China
Prior art keywords
sarcoma
ewing
acid
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080019229.3A
Other languages
English (en)
Other versions
CN113710658B (zh
Inventor
湛筱乐
屠礼凡
杨朝强
张喜全
王训强
许婕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN113710658A publication Critical patent/CN113710658A/zh
Application granted granted Critical
Publication of CN113710658B publication Critical patent/CN113710658B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明属于医药领域，提供用于治疗尤因肉瘤的喹啉类化合物或其药学上可接受的盐，具体涉及化合物I或其药学上可接受的盐在制备用于治疗尤因肉瘤的药物中的应用，以及化合物I或其药学上可接受的盐与第二治疗剂联合在制备用于治疗尤因肉瘤的联用药物中的应用，化合物I的化学名称为1‑[[[4‑(4‑氟‑2‑甲基‑1H‑吲哚‑5‑基)氧基‑6‑甲氧基喹啉‑7‑基]氧基]甲基]环丙胺。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN202080019229.3A 2019-04-19 2020-04-20 用于治疗尤因肉瘤的喹啉类化合物或其药学上可接受的盐 Active CN113710658B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910315417 2019-04-19
CN201910315417X 2019-04-19
PCT/CN2020/085552 WO2020211860A1 (zh) 2019-04-19 2020-04-20 用于治疗尤因肉瘤的喹啉类化合物或其药学上可接受的盐

Publications (2)

Publication Number Publication Date
CN113710658A true CN113710658A (zh) 2021-11-26
CN113710658B CN113710658B (zh) 2023-11-21

Family

ID=72837048

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080019229.3A Active CN113710658B (zh) 2019-04-19 2020-04-20 用于治疗尤因肉瘤的喹啉类化合物或其药学上可接受的盐

Country Status (8)

Country Link
US (1) US20220193067A1 (zh)
EP (1) EP3957631A4 (zh)
JP (1) JP2022529295A (zh)
KR (1) KR20220003560A (zh)
CN (1) CN113710658B (zh)
AU (1) AU2020259565A1 (zh)
CA (1) CA3137204A1 (zh)
WO (1) WO2020211860A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112279838B (zh) * 2020-10-29 2021-07-13 苏州富士莱医药股份有限公司 一种吡咯替尼的制备方法
CN112110899B (zh) * 2020-10-29 2021-07-30 苏州富士莱医药股份有限公司 一种吡咯替尼的合成方法
CN112358467B (zh) * 2020-10-29 2021-07-30 苏州富士莱医药股份有限公司 一种吡咯替尼的制备工艺
EP4237420A1 (en) * 2020-10-30 2023-09-06 Athenex R&D, LLC Polymorphisms of hm30181 mesylate
CN112316149A (zh) * 2020-11-11 2021-02-05 王海涛 一种治疗tp53突变的晚期难治性实体瘤的药物及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105311029A (zh) * 2014-06-06 2016-02-10 正大天晴药业集团股份有限公司 抗肿瘤活性的喹啉衍生物
CN105311030A (zh) * 2014-06-06 2016-02-10 正大天晴药业集团股份有限公司 用于抗肿瘤的螺取代化合物
CN107771078A (zh) * 2015-05-04 2018-03-06 爱德程医药有限公司 用于制备抗癌剂1‑((4‑(4‑氟‑2‑甲基‑1h‑吲哚‑5‑基氧基)‑6‑甲氧基喹啉‑7‑基氧基)甲基)环丙胺、其结晶形式和其盐的方法
CN107970241A (zh) * 2018-01-22 2018-05-01 上海市第人民医院 一种新型酪氨酸激酶抑制剂-安罗替尼在骨肉瘤的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8148532B2 (en) 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
CN103664892B (zh) 2010-08-01 2015-09-02 正大天晴药业集团股份有限公司 喹啉衍生物的结晶

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105311029A (zh) * 2014-06-06 2016-02-10 正大天晴药业集团股份有限公司 抗肿瘤活性的喹啉衍生物
CN105311030A (zh) * 2014-06-06 2016-02-10 正大天晴药业集团股份有限公司 用于抗肿瘤的螺取代化合物
CN107771078A (zh) * 2015-05-04 2018-03-06 爱德程医药有限公司 用于制备抗癌剂1‑((4‑(4‑氟‑2‑甲基‑1h‑吲哚‑5‑基氧基)‑6‑甲氧基喹啉‑7‑基氧基)甲基)环丙胺、其结晶形式和其盐的方法
CN107970241A (zh) * 2018-01-22 2018-05-01 上海市第人民医院 一种新型酪氨酸激酶抑制剂-安罗替尼在骨肉瘤的应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GANGYANG WANG 等: "Anlotinib, a novel small molecular tyrosine kinase inhibitor,suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma", 《INTERNATIONAL JOURNAL OF CANCER》 *
邓雪松: "骨尤文肉瘤的治疗进展" *
邓雪松: "骨尤文肉瘤的治疗进展", 《中国全科医学》 *

Also Published As

Publication number Publication date
EP3957631A4 (en) 2023-01-11
AU2020259565A1 (en) 2021-12-02
CN113710658B (zh) 2023-11-21
EP3957631A1 (en) 2022-02-23
JP2022529295A (ja) 2022-06-20
WO2020211860A1 (zh) 2020-10-22
CA3137204A1 (en) 2020-10-22
KR20220003560A (ko) 2022-01-10
US20220193067A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
CN113710658B (zh) 用于治疗尤因肉瘤的喹啉类化合物或其药学上可接受的盐
US10888559B2 (en) Quinoline derivatives for non-small cell lung cancer
WO2023035223A1 (zh) 药物组合物及其用途
WO2023093663A1 (en) Pharmaceutical composition and use thereof
CN112043831A (zh) 用于联合治疗乳腺癌的喹啉类化合物
CN111840289A (zh) 用于治疗骨巨细胞瘤的喹啉类化合物或其药学上可接受的盐
CN113116895A (zh) 用于治疗神经母细胞瘤的喹啉衍生物
CN112584834B (zh) 用于治疗结外nk/t细胞淋巴瘤的喹啉衍生物
WO2023168036A1 (en) Method of treatment including kras g12c inhibitors and shp2 inhibitors
US11419862B2 (en) Quinoline derivative for treatment of nasopharyngeal carcinoma
CN111821302A (zh) 用于联合治疗软骨肉瘤的喹啉类化合物
US20230038138A1 (en) Combination therapy for treating cancer
CN111821459A (zh) 用于联合治疗骨肉瘤的喹啉类化合物
WO2020228656A1 (zh) 用于联合治疗软组织肉瘤的喹啉衍生物
KR20240074779A (ko) 약학적 조성물 및 이의 용도
CN112533600A (zh) 用于治疗小细胞肺癌的喹啉衍生物
CN112105361A (zh) 用于治疗非小细胞肺癌的喹啉衍生物
CN117956999A (zh) 杂芳基氧基萘类化合物的用途
CN112294813A (zh) 喹啉衍生物在治疗脊索瘤中的用途
CN111110681A (zh) 喹啉衍生物联合卡培他滨在治疗肝癌的用途
NZ786604A (en) Combination therapy with notch and cdk4/6 inhibitors for the treatment of

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CB03 Change of inventor or designer information

Inventor after: Zhan Xiaole

Inventor after: Tu Lifan

Inventor after: Yang Chaoqiang

Inventor after: Zhang Xiquan

Inventor after: Wang Xunqiang

Inventor after: Xu Jie

Inventor after: Xu Ping

Inventor after: Wang Chengqian

Inventor before: Zhan Xiaole

Inventor before: Tu Lifan

Inventor before: Yang Chaoqiang

Inventor before: Zhang Xiquan

Inventor before: Wang Xunqiang

Inventor before: Xu Jie

CB03 Change of inventor or designer information